Pediatr. praxi. 2010;11(4):246-250

Presence of the 13-valent pneumococcal conjugate vaccine

doc.MUDr.Roman Chlíbek, Ph.D., MUDr.Jan Smetana, Ph.D., RNDr.Vanda Boštíková, Ph.D.

Katedra epidemiologie, Fakulta vojenského zdravotnictví Univerzity obrany Hradec Králové

At present, the possibility of prevention of pneumococcal disease is expanding. There are available 7 -, 10 – and 13-valent conjugate vaccines

(PCV-7, PCV-10, PCV-13). PCV-13 (Prevenar 13) was registered as the newest in 2009. This vaccine contains a protein carrier identical

as the previous vaccine PCV-7 (Prevenar) and plus six new serotypes (ST) Streptococcus pneumoniae: 1, 3, 5, 6A, 7F and 19A. The reasons

of addition new serotypes were their clinical severity and global presence. Vaccine PCV-13 at any assessment (immunogenicity, safety)

demonstrated non-inferiority compared with PCV-7. PCV-13 vaccine should be effective in preventing otitis media, and has the broader

serotype coverage. Because of the age indications PCV and PCV-7–13 are only one of conjugate vaccines intended for at-risk children

under 5 years of age. Pneumococcal vaccination in newborns and infants is the first voluntary based vaccination as part of the national

immunization schedule and is the first reimbursed by public health insurance. With access of new vaccines competitive environment is

more open, which allows pediatricians to offer more options in prevention of pneumococcal disease and for parents have the right to

require vaccine of their choice.

Keywords: 13valent pneumococcal conjugate vaccine, pneumococcal vaccine, pneumococcal disease

Published: October 1, 2010  Show citation